The approval granted by the US Food and Drug Administration (USFDA) is to market the Scopolamine transdermal system of dosage 1 mg/3 days, Zydus Lifesciences said in a regulatory filing. New Delhi: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback